NCT04209816View on ClinicalTrials.gov

Genetic Pathways Leading to Fatty Liver and Atherogenic Dyslipidemia

Enrolling by invitationOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2028

Conditions
Non-alcoholic Fatty LiverAtherogenic DyslipidemiaInsulin Resistance
Interventions
DIAGNOSTIC_TEST

Lipoprotein kinetics

Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.

Trial Locations (2)

Unknown

RPU Clinical and Molecular Metabolism, Biomedicum, Helsinki

Wallenberg Laboratory, Gothenburg

All Listed Sponsors
collaborator

Göteborg University

OTHER

lead

Marja-Riitta Taskinen

OTHER